[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR128483A2 - Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos - Google Patents

Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos

Info

Publication number
AR128483A2
AR128483A2 ARP230100302A ARP230100302A AR128483A2 AR 128483 A2 AR128483 A2 AR 128483A2 AR P230100302 A ARP230100302 A AR P230100302A AR P230100302 A ARP230100302 A AR P230100302A AR 128483 A2 AR128483 A2 AR 128483A2
Authority
AR
Argentina
Prior art keywords
compound
crystalline compound
solid forms
crystalline
hydroxypyridin
Prior art date
Application number
ARP230100302A
Other languages
English (en)
Inventor
Copp James Densmore
Ann W Newman
Anne Luong
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of AR128483A2 publication Critical patent/AR128483A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Formas sólidas que comprenden el ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, las composiciones que comprenden las formas sólidas, los métodos de elaboración de las formas sólidas y los métodos de uso para el tratamiento de diversas enfermedades o trastornos. Reivindicación 1: Un compuesto cristalino (I) caracterizado porque tiene la fórmula: (1), que tiene un patrón de difracción de polvos por rayos X que comprende uno, dos, tres, cuatro o cinco picos a alrededor de 18,1, 20,3, 22,9, 24,0, y 26,3º 2q; y en donde el compuesto cristalino (I) está de manera considerable libre de cualquier otro compuesto cristalino (I). Reivindicación 26: Una composición farmacéutica caracterizada porque comprende un compuesto cristalino de una cualquiera de las reivindicaciones 1 a 25. Reivindicación 32: Un método para la elaboración de un compuesto cristalino (I), caracterizado porque comprende, a) la preparación de una solución del compuesto (I) en un solvente orgánico; b) el cambio de la condición de la solución hasta sobresaturación para provocar la formación de cristales; y c) la separación de los cristales; en donde el compuesto cristalino (I) está de manera considerable libre de cualquier forma cristalina del compuesto (I); o en donde el compuesto cristalino (I), está de manera considerable libre de un compuesto de fórmula (2); determinado por CG / EM; o en donde el compuesto cristalino (I), está de manera considerable libre de compuesto (I) amorfo.
ARP230100302A 2013-11-15 2023-02-08 Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos AR128483A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361904803P 2013-11-15 2013-11-15

Publications (1)

Publication Number Publication Date
AR128483A2 true AR128483A2 (es) 2024-05-15

Family

ID=53058045

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140104298A AR099354A1 (es) 2013-11-15 2014-11-14 Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
ARP230100302A AR128483A2 (es) 2013-11-15 2023-02-08 Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140104298A AR099354A1 (es) 2013-11-15 2014-11-14 Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos

Country Status (24)

Country Link
US (7) US9701636B2 (es)
EP (2) EP3068394A4 (es)
JP (4) JP2016537365A (es)
KR (2) KR102381295B1 (es)
CN (2) CN114890943A (es)
AR (2) AR099354A1 (es)
AU (4) AU2014348523B2 (es)
BR (1) BR112016011065B1 (es)
CA (1) CA2930128A1 (es)
CL (1) CL2016001150A1 (es)
CR (2) CR20200220A (es)
DO (1) DOP2016000109A (es)
IL (2) IL245634A0 (es)
MA (1) MA39033A1 (es)
MX (3) MX2021001169A (es)
MY (1) MY180626A (es)
PE (1) PE20160945A1 (es)
PH (1) PH12016500866A1 (es)
RU (2) RU2016123382A (es)
SA (1) SA516371129B1 (es)
SG (2) SG10202012791TA (es)
TW (4) TWI788702B (es)
WO (1) WO2015073779A1 (es)
ZA (2) ZA201603189B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3357911T (pt) 2006-06-26 2022-07-11 Akebia Therapeutics Inc Inibidores da prolil-hidroxilase e métodos de utilização
NO2686520T3 (es) 2011-06-06 2018-03-17
ES2974273T3 (es) 2013-06-13 2024-06-26 Akebia Therapeutics Inc Composiciones y métodos para tratar la anemia
KR102381295B1 (ko) 2013-11-15 2022-03-31 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
CA2937349A1 (en) * 2014-01-23 2015-07-30 Akebia Therapeutics, Inc. Compositions and methods for treating ocular diseases
JP2018502882A (ja) 2015-01-23 2018-02-01 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ２−（５−（３−フルオロフェニル）−３−ヒドロキシピコリンアミド）酢酸の固体形態、その組成物及び使用
PL3277270T3 (pl) 2015-04-01 2022-02-14 Akebia Therapeutics, Inc. Kompozycje i sposoby leczenia niedokrwistości
CN105837502A (zh) * 2016-04-05 2016-08-10 湖南欧亚生物有限公司 一种Vadadustat的合成方法
MX2019006883A (es) * 2016-12-13 2019-10-21 Crystal Pharmaceutical Suzhou Co Ltd Formas cristalinas novedosas de ácido {[5-(3-clorofenil)-3-idroxip iridina-2-carbonilo] amino} acético y procedimientos para la preparación del mismo.
WO2019028150A1 (en) * 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
US11970450B2 (en) 2018-11-28 2024-04-30 Sandoz Ag Multi-component crystals of an orally available HIF prolyl hydroxylase inhibitor
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
IT202000014116A1 (it) 2020-06-12 2021-12-12 Olon Spa Nuovo composto cristallino di vadadustat
WO2021257800A1 (en) * 2020-06-19 2021-12-23 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
CN115996720A (zh) * 2020-09-04 2023-04-21 广东东阳光药业有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
JP2024503377A (ja) 2021-01-08 2024-01-25 アケビア セラピューティクス インコーポレイテッド バダデュスタットを使用した治療方法
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
WO2022187142A1 (en) * 2021-03-01 2022-09-09 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
BR8807740A (pt) 1988-07-25 1990-10-16 V Kurgansky Nauchny Ts Vosstan Aparelho de tracao para reconstrucao plastica da mao
TW219933B (es) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
CA2253282A1 (en) 1996-04-30 1997-11-06 Hoechst Aktiengesellschaft 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and their use as drugs
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
CN1282319A (zh) 1997-10-09 2001-01-31 小野药品工业株式会社 氨基丁酸衍生物
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
AU757868B2 (en) 1998-03-23 2003-03-06 Aventis Pharmaceuticals Inc. Piperididinyl and N-amidinopiperidinyl derivatives
EP1107974B1 (en) 1998-08-27 2006-08-02 Teva Pharmaceutical Industries Ltd. Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
DE69929462T2 (de) 1998-11-27 2006-09-07 Teva Pharmaceutical Industries Ltd. Sertralin hydrochlorid form
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
CZ2002404A3 (cs) 1999-08-11 2002-06-12 Teva Pharmaceutical Industries Ltd. Polymorfní formy torsemidu
EP2206497A1 (en) 1999-11-17 2010-07-14 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
AU779306B2 (en) 1999-12-14 2005-01-13 Teva Gyogyszergyar Reszvenytarsasag Novel forms of pravastatin sodium
JP2003517011A (ja) 1999-12-16 2003-05-20 テバ ファーマシューティカル インダストリーズ リミティド レフルノミドの新規な製法及び新しい結晶形態
WO2001044262A1 (en) 1999-12-16 2001-06-21 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph iv
ES2281374T3 (es) 1999-12-21 2007-10-01 Teva Pharmaceutical Industries Ltd. Nuevos polimorfos de hidrocloruro de sertralina, procedimientos para su preparacion, composiciones que los contienen y metodos para su utilizacion.
CZ20022332A3 (cs) 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
SI1280535T1 (es) 2000-01-11 2005-08-31 Teva Pharma
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
KR100729298B1 (ko) 2000-07-27 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정질의 순수한 모다피닐 및 이의 제조 방법
AU2002241764A1 (en) 2000-10-19 2002-06-18 Teva Pharmaceutical Industries Ltd. Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US20020183553A1 (en) 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
KR20030042038A (ko) 2000-10-30 2003-05-27 테바 파마슈티컬 인더스트리즈 리미티드 온단세트론 히드로클로라이드의 신규한 결정 형태 및용매화물 형태와 이들의 제조 방법
US6605636B2 (en) 2000-11-03 2003-08-12 Teva Pharmaceutical Industries Ltd. Atorvastatin hemi-calcium form VII
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
JP2004526706A (ja) 2001-02-12 2004-09-02 テバ ファーマシューティカル インダストリーズ リミティド オクスカルバゼピンの新しい結晶形態及びそれらの調製方法
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
AU2002241154A1 (en) 2001-03-21 2002-10-03 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
WO2002080857A2 (en) 2001-04-09 2002-10-17 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
JP2005523874A (ja) 2001-08-01 2005-08-11 テバ ジョジセルジャール レースベニュタールシャシャーグ Ｎ−〔３−（３−シアノピラゾロ〔１，５−ａ〕ピリミジン−７−イル）フェニル〕−Ｎ−エチルアセタミド（ザレプロン）の精製方法、及び当該方法により得られうるザレプロンの結晶型
KR100774271B1 (ko) 2001-09-07 2007-11-08 테바 파마슈티컬 인더스트리즈 리미티드 발라사이클로비르 염산염의 결정질 형태
WO2003028664A2 (en) 2001-10-03 2003-04-10 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and forms thereof
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
CA2465913A1 (en) 2001-11-08 2003-05-15 Judith Aronhime Polymorphs of fexofenadine base
CN1612866A (zh) 2001-11-14 2005-05-04 特瓦制药工业有限公司 无定形和结晶形的氯沙坦钾及其制备方法
AU2002362061A1 (en) 2001-12-04 2003-06-17 Biogal Gyogyszergyar Rt Preparation of orlistat and orlistat crystalline forms
CN102552263A (zh) 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
PL370802A1 (en) 2001-12-18 2005-05-30 Teva Pharmaceutical Industries Ltd. Polymorphs of clopidogrel hydrogensulfate
WO2003065975A2 (en) 2001-12-28 2003-08-14 Biogal Gyogyszergyar Rt Processes for preparing crystalline and amorphous mupirocin calcium
CN1298322C (zh) 2002-01-15 2007-02-07 特瓦制药工业有限公司 卡维地洛的结晶固体及其制备方法
CA2475864A1 (en) 2002-02-15 2003-08-28 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
CA2479668A1 (en) 2002-03-20 2003-10-02 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
EP1476442A2 (en) 2002-03-27 2004-11-17 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
JP3803672B2 (ja) 2002-04-11 2006-08-02 テバ ファーマシューティカル インダストリーズ リミティド 新規多形及び偽多形
EP1499581A1 (en) 2002-04-29 2005-01-26 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
PL373192A1 (en) 2002-04-30 2005-08-22 Teva Gyogyszergyar Reszvenytarsasag Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
KR20040106518A (ko) 2002-05-10 2004-12-17 테바 파마슈티컬 인더스트리즈 리미티드 가티플록사신의 신규한 결정 형태
DE03757471T1 (de) 2002-06-10 2005-09-01 Teva Pharmaceutical Industries Ltd. Polymorphe form xvi von fexofenadin-hydrochlorid
CN1674902A (zh) 2002-06-14 2005-09-28 特瓦制药工业有限公司 新晶型的加替沙星
WO2004009532A1 (en) 2002-07-18 2004-01-29 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US20040022764A1 (en) * 2002-07-31 2004-02-05 Hanan Polansky Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
EP1545530A1 (en) 2002-08-06 2005-06-29 Teva Pharmaceutical Industries Limited Novel crystalline forms of gatifloxacin
WO2004018470A2 (en) 2002-08-26 2004-03-04 Teva Pharmaceutical Industries Ltd. Crystalline solid famciclovir forms i, ii, iii and preparation thereof
US20050043329A1 (en) 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
EP1572643A2 (en) 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
WO2004054583A1 (en) 2002-12-12 2004-07-01 Teva Pharmaceutical Industries Ltd. Crystalline forms of gatifloxacin and processes for preparation
US7323459B2 (en) 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
US20040242619A1 (en) 2003-03-12 2004-12-02 Toth Zoltan G. Processes for preparation of polymorphic forms of desloratadine
EP1601667A2 (en) 2003-03-12 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline and amorphous solids of pantoprazole and processes for their preparation
EP1511739B1 (en) 2003-03-17 2008-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of valsartan
WO2004103999A1 (en) 2003-05-15 2004-12-02 TEVA Gyógyszergyár Részvénytársaság AZTREONAM β POLYMORPH WITH VERY LOW RESIDUAL SOLVENT CONTENT
EP1638972A2 (en) 2003-06-02 2006-03-29 Teva Pharmaceutical Industries Limited Novel crystalline forms of valacyclovir hydrochloride
EP1546146A1 (en) 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
PT1644336E (pt) 2003-06-06 2011-04-21 Fibrogen Inc Compostos de heteroarilo que contêm azoto e sua utilização no aumento da eritropoetina endógena
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
EP1790634A3 (en) 2003-06-18 2007-06-13 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal form and processes for preparing it
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
EP1567533B1 (en) 2003-07-03 2009-03-11 Teva Pharmaceutical Industries Ltd. Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
WO2005051921A1 (en) 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
ES2374922T3 (es) 2003-12-16 2012-02-23 Teva Pharmaceutical Industries Ltd. Procedimientos de preparación de formas cristalinas de aripiprazol.
WO2005058819A2 (en) 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
EP1592688A2 (en) 2003-12-18 2005-11-09 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
EP1708708A1 (en) 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
US20050187244A1 (en) 2004-01-30 2005-08-25 Entire Interest. Montelukast sodium polymorphs
EP1713795A2 (en) 2004-02-11 2006-10-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
WO2005108370A1 (ja) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
JP2007532687A (ja) 2004-04-26 2007-11-15 テバ ファーマシューティカル インダストリーズ リミティド フェキソフェナジン塩酸塩の結晶形およびその製造方法
EP1656339A1 (en) 2004-05-07 2006-05-17 Teva Pharmaceutical Industries Ltd Polymorphic forms of nateglinide
WO2005116031A1 (en) 2004-05-18 2005-12-08 Teva Pharmaceutical Industries Ltd. Drying process for preparing crystalline solid famciclovir
CA2556920A1 (en) 2004-05-20 2005-12-01 Teva Pharmaceutical Fine Chemicals S.R.L. Levalbuterol hydrochloride polymorph a
MX2007000087A (es) 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
WO2006004922A1 (en) 2004-06-29 2006-01-12 Teva Pharmaceutical Industries Ltd. Crystalline form iv of linezolid
WO2006025939A1 (en) 2004-07-01 2006-03-09 Teva Pharmaceutical Industries Ltd. Crystalline forms of 1,24(s)-dihydroxy vitamin d2
CA2573784A1 (en) 2004-07-20 2006-02-02 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Crystalline mycophenolate sodium
JP2007505944A (ja) 2004-07-22 2007-03-15 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウム及びその調製の方法
CN1976894A (zh) 2004-07-22 2007-06-06 特瓦药物精化学品股份有限公司 阿托莫西汀盐酸盐的多形体
JP4559431B2 (ja) 2004-08-23 2010-10-06 テバ ファーマシューティカル インダストリーズ リミティド 固体及び結晶イバンドロネートナトリウム及びその調製方法
KR20070052780A (ko) 2004-09-21 2007-05-22 테바 파마슈티컬 인더스트리즈 리미티드 결정질 클로피도그렐 브롬산염 및 이의 제조 방법
JP2008514641A (ja) 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
US20060111571A1 (en) 2004-11-02 2006-05-25 Shlomit Wizel Tadalafil crystal forms and processes for preparing them
WO2006050509A2 (en) 2004-11-03 2006-05-11 Teva Pharmaceutical Industries Ltd. Amorphous and polymorphic forms of telmisartan sodium
EP1812428A2 (en) 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
CA2584365A1 (en) 2004-12-01 2006-06-08 Teva Gyogyszergyar Zartkoeruen Mukoedo Reszvenytarsasag Ascomycin crystalline forms and preparation thereof
WO2006060808A1 (en) 2004-12-03 2006-06-08 Teva Pharmaceutical Industries Ltd. Ezetimibe polymorphs
EP1836154A1 (en) 2005-01-11 2007-09-26 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of memantine hydrochloride
WO2006081515A2 (en) 2005-01-27 2006-08-03 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride polymorphs
US20080213404A1 (en) 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
EP1866295A2 (en) 2005-02-24 2007-12-19 Teva Pharmaceutical Industries Ltd Processes for the preparation of linezolid intermediate
MX2007010392A (es) 2005-02-24 2007-10-17 Teva Pharma Cristales de ladostigil tratrato, metodos de produccion y composiciones farmaceuticas de los mismos.
US7399871B2 (en) 2005-03-08 2008-07-15 Teva Pharmaceutical Industries Ltd. Crystal forms of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof
US20060270684A1 (en) 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
MX2007012396A (es) 2005-04-06 2007-11-20 Teva Pharma Formas cristalinas de pregabalina.
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
CA2604760C (en) 2005-05-23 2012-06-26 Cadbury Adams Usa Llc Taste potentiator compositions and beverages containing same
EP1975150A1 (en) 2005-05-23 2008-10-01 Teva Pharmaceutical Industries Ltd. Cinacalcet salts
WO2006133391A2 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
EP1893559A2 (en) 2005-06-09 2008-03-05 Teva Pharmaceutical Industries Ltd Process for preparation of sertraline hydrochloride form i
KR20070088507A (ko) 2005-06-09 2007-08-29 테바 파마슈티컬 인더스트리즈 리미티드 카베딜올의 결정질 형태 및 이것의 제조 방법
JP5410751B2 (ja) 2005-06-15 2014-02-05 ファイブローゲン、インコーポレーテッド がん治療のための化合物および方法
US20070112057A1 (en) 2005-06-22 2007-05-17 Santiago Ini Polymorphic forms of tegaserod maleate
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007038676A2 (en) 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
WO2007047194A2 (en) 2005-10-11 2007-04-26 Dana-Farber Cancer Institute, Inc. Methods for treating mitf-related disorders
CN101291911B (zh) 2005-10-19 2014-08-13 泰华制药工业有限公司 拉奎尼莫钠晶体及其制备方法
WO2007053722A2 (en) 2005-10-31 2007-05-10 Teva Pharmaceutical Industries Ltd. Crystalline form of cefdinir cesium salt
WO2007053724A2 (en) 2005-10-31 2007-05-10 Teva Pharmaceutical Industries Ltd. Crystalline forms of cefdinir potassium salt
WO2007059307A2 (en) 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
EP1828098A1 (en) 2005-11-22 2007-09-05 Teva Pharmaceutical Industries Ltd Crystal forms of cinacalcet hci and processes for their preparation
ES2446416T3 (es) 2005-12-09 2014-03-07 Amgen, Inc. Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos
EP1966133A2 (en) 2005-12-13 2008-09-10 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
WO2007081889A2 (en) 2006-01-05 2007-07-19 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Production of dolasetron
BRPI0706377A2 (pt) 2006-01-09 2011-03-22 Btg Int Ltd moduladores de fator -1 induzìvel por hipoxia e usos relacionados
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
WO2007084697A2 (en) 2006-01-18 2007-07-26 Teva Pharmaceutical Industries Ltd. Process for preparing a crystalline form of tegaserod maleate
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
US20070293702A1 (en) 2006-02-21 2007-12-20 Viviana Braude Novel crystalline forms of armodafinil and preparation thereof
CA2642180A1 (en) 2006-02-27 2007-09-07 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium novel forms and preparation therof
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
WO2007109799A2 (en) 2006-03-23 2007-09-27 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
JP2009537558A (ja) 2006-05-16 2009-10-29 スミスクライン・ビーチャム・コーポレイション プロリルヒドロキシラーゼ阻害剤
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
PT3357911T (pt) 2006-06-26 2022-07-11 Akebia Therapeutics Inc Inibidores da prolil-hidroxilase e métodos de utilização
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
CA2683758A1 (en) 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
AU2008241577B2 (en) 2007-04-18 2011-04-07 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
EP2150251B9 (en) 2007-05-04 2013-02-27 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
CA2685942A1 (en) 2007-05-16 2008-11-27 Merck & Co., Inc. Spiroindalones
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
WO2009037570A2 (en) 2007-08-10 2009-03-26 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JP2011503094A (ja) 2007-11-08 2011-01-27 ジェネンテック， インコーポレイテッド 抗ｂ因子抗体およびそれらの使用
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
WO2009073497A2 (en) 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009070644A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
JP2011507894A (ja) 2007-12-19 2011-03-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
NO2686520T3 (es) 2011-06-06 2018-03-17
EP2717870B1 (en) 2011-06-06 2017-09-27 Akebia Therapeutics Inc. Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer
US9206134B2 (en) 2011-07-22 2015-12-08 Beijing Betta Pharmaceuticals Co. Ltd. Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
US8772895B2 (en) 2011-11-28 2014-07-08 Taiwan Semiconductor Manufacturing Company, Ltd. Dark current reduction for back side illuminated image sensor
EP2637274B1 (en) 2012-03-05 2022-05-04 Vetco Gray Scandinavia AS Power cable termination arrangement
ES2974273T3 (es) 2013-06-13 2024-06-26 Akebia Therapeutics Inc Composiciones y métodos para tratar la anemia
KR102381295B1 (ko) 2013-11-15 2022-03-31 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
CA2937349A1 (en) 2014-01-23 2015-07-30 Akebia Therapeutics, Inc. Compositions and methods for treating ocular diseases
JP2018502882A (ja) 2015-01-23 2018-02-01 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ２−（５−（３−フルオロフェニル）−３−ヒドロキシピコリンアミド）酢酸の固体形態、その組成物及び使用
CA2979985A1 (en) 2015-03-20 2016-09-29 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
PL3277270T3 (pl) 2015-04-01 2022-02-14 Akebia Therapeutics, Inc. Kompozycje i sposoby leczenia niedokrwistości
MX2019006883A (es) 2016-12-13 2019-10-21 Crystal Pharmaceutical Suzhou Co Ltd Formas cristalinas novedosas de ácido {[5-(3-clorofenil)-3-idroxip iridina-2-carbonilo] amino} acético y procedimientos para la preparación del mismo.
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2021087144A1 (en) 2019-10-31 2021-05-06 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Also Published As

Publication number Publication date
EP3578546A1 (en) 2019-12-11
JP2020183408A (ja) 2020-11-12
TW201605801A (zh) 2016-02-16
EP3068394A1 (en) 2016-09-21
JP2022176961A (ja) 2022-11-30
AU2022259767B2 (en) 2024-08-15
US11690836B2 (en) 2023-07-04
US10149842B2 (en) 2018-12-11
SA516371129B1 (ar) 2019-07-28
AU2022259767A1 (en) 2022-12-01
US20190290624A1 (en) 2019-09-26
BR112016011065B1 (pt) 2022-10-25
AU2020294308B2 (en) 2022-08-11
KR102381295B1 (ko) 2022-03-31
NZ719970A (en) 2022-03-25
CL2016001150A1 (es) 2016-12-09
US10596158B2 (en) 2020-03-24
US11065237B2 (en) 2021-07-20
KR102495018B1 (ko) 2023-02-06
MA39033A1 (fr) 2017-11-30
US20200345711A1 (en) 2020-11-05
RU2021125455A (ru) 2021-10-05
US9987262B2 (en) 2018-06-05
BR112016011065A2 (pt) 2017-08-08
DOP2016000109A (es) 2016-08-31
ZA201905255B (en) 2020-11-25
TW202335670A (zh) 2023-09-16
JP2016537365A (ja) 2016-12-01
IL281648A (en) 2021-05-31
KR20160083118A (ko) 2016-07-11
TW202126300A (zh) 2021-07-16
AU2014348523A1 (en) 2016-06-09
MX2021007268A (es) 2021-07-15
CN105916502A (zh) 2016-08-31
CA2930128A1 (en) 2015-05-21
US20220040159A1 (en) 2022-02-10
US9701636B2 (en) 2017-07-11
MX2016006271A (es) 2017-05-04
BR112016011065A8 (pt) 2020-04-22
CN114890943A (zh) 2022-08-12
KR20220042498A (ko) 2022-04-05
AU2019202144A1 (en) 2019-04-18
JP2019167353A (ja) 2019-10-03
AU2020294308A1 (en) 2021-02-18
US20150141467A1 (en) 2015-05-21
AR099354A1 (es) 2016-07-20
MY180626A (en) 2020-12-03
RU2016123382A (ru) 2017-12-20
EP3068394A4 (en) 2017-04-26
SG10201803862UA (en) 2018-06-28
PH12016500866A1 (en) 2016-06-20
AU2019202144B2 (en) 2020-10-08
IL245634A0 (en) 2016-06-30
CR20160222U (es) 2016-08-26
WO2015073779A1 (en) 2015-05-21
TW201946625A (zh) 2019-12-16
TWI665190B (zh) 2019-07-11
NZ759132A (en) 2022-03-25
US20240122910A1 (en) 2024-04-18
CR20200220A (es) 2020-11-18
MX2021001169A (es) 2023-02-10
ZA201603189B (en) 2019-11-27
TWI788702B (zh) 2023-01-01
TWI846166B (zh) 2024-06-21
SG10202012791TA (en) 2021-01-28
US20180280365A1 (en) 2018-10-04
US20170258773A1 (en) 2017-09-14
PE20160945A1 (es) 2016-09-26
AU2014348523B2 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
AR128483A2 (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
SV2016005229A (es) Inhibidores de syk
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
DOP2014000133A (es) Triazolopiridinas sustituidas
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
AR066130A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
BR112016017996A2 (pt) 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
CL2015000019A1 (es) Composicion farmaceutica que comprende rifaximina cristalina, polimorfa o amorfa, como un hidrato o solvato y/o en una mezcla de la misma y uno o mas aminoacidos; procedimiento de preparacion de la composicion; cristales de rifaximina; su procedimiento de preparacion.
BR112017015852A2 (pt) forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
UY35746A (es) Derivados de fenilalanina sustituidos
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
NI201200194A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
CY1122598T1 (el) Οφθαλμικη φαρμακευτικη συνθεση περιεχουσα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτης